Position in DNLI
as of Jun 30, 2026
· filed Aug 12, 2026
Position Value
$13,361,102
+$3,558,677 QoQ
Shares Held
519,483
+1.8% QoQ
Ownership
0.325%
of shares outstanding
% of Portfolio
0.16%
of 13F equity value
Holder Rank
#46
of 290 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 85%
Shared 0%
None 15%
Common Shares in DNLI Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026SEGALL BRYANT & HAMILL, LLC holds $322,746,195 across 29 Biotechnology names. DNLI ranks #12 (4.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | PTGX |
Protagonist Therapeutics, Inc
|
214,724 | $26,320,867 | |
| 2 | HALO |
Halozyme Therapeutics, Inc.
|
317,924 | $24,883,911 | |
| 3 | KRYS |
Krystal Biotech, Inc.
|
65,211 | $24,236,972 | |
| 4 | PTCT |
Ptc Therapeutics, Inc.
|
271,735 | $22,165,423 | |
| 5 | TECH |
BIO-TECHNE Corp
|
312,035 | $22,045,272 | |
| 6 | CYTK |
Cytokinetics Inc
|
257,063 | $21,899,196 | |
| 7 | MIRM |
Mirum Pharmaceuticals, Inc.
|
178,980 | $20,953,188 | |
| 8 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
37,072 | $18,414,774 |
All Filings in DNLI
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $13,361,102 | 519,483 | Shares | Sole | 2026-08-12 | |
| 2026-03-31 | $9,802,425 | 510,543 | Shares | Sole | 2026-05-22 | |
| 2025-12-31 | $8,865,870 | 537,000 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $7,448,150 | 512,958 | Shares | Sole | 2025-11-12 | |
| 2025-06-30 | $7,002,820 | 500,559 | Shares | Sole | 2025-08-12 | |
| 2025-03-31 | $3,822,084 | 281,139 | Shares | Sole | 2025-05-02 | |
| 2024-12-31 | $5,891,348 | 289,075 | Shares | Sole | 2025-02-11 | |
| No filing history on record for this holder in this stock. | ||||||